Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35 p.m. ET in New York.

Rhea-AI Summary

Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35 p.m. ET in New York.

The live and archived webcasts will be accessible via the Events page on Caribou’s website for at least 30 days.

Market Context

This announcement highlights CRBU’s participation in a major healthcare investor conference, extendi...

Analysis

This announcement highlights CRBU’s participation in a major healthcare investor conference, extending a pattern of regular visibility events. The fireside chat and webcast on June 4, 2026 offer management another forum to discuss its CRISPR-based CAR-T programs and prior milestones, including RMAT designation for CB-011 and FDA alignment on vispa-cel’s pivotal design. Investors may watch for any incremental clinical, regulatory, or financing commentary alongside these appearances, given earlier disclosures on cash of $118.6M and runway into 2H 2027.

Key Figures

Share price: $2.16 Volume: 1,937,955 shares 52-week high: $3.535 +5 more

Share price

$2.16

Pre-news current price for CRBU

Volume

1,937,955 shares

Today’s trading volume before this news

52-week high

$3.535

Trailing 52-week period

52-week low

$0.9573

Trailing 52-week period

Cash balance

$118.6M

Q1 2026 cash, cash equivalents, and marketable securities

Net loss

$25.1M

Q1 2026 net loss as reported in 10-Q/8-K

Cash runway

Into 2H 2027

Management’s guidance on funding current operating plan

Overall response rate

92%

CB-011 CaMMouflage phase 1, 12 BCMA-naïve patients at expansion dose

Historical Context

5 past events · Latest: May 13

5 events

1. May 13

   Conference participation

   24h Move

   +0.9%

   Announced fireside chat at H.C. Wainwright BioConnect investor conference.

2. May 12

   Clinical presentations

   24h Move

   +0.0%

   Planned EHA oral presentations on vispa-cel and CB-011 phase 1 data.

3. May 07

   Earnings and update

   24h Move

   +3.2%

   Q1 2026 results plus FDA alignment on ANTLER-3 and RMAT for CB-011.

4. May 05

   Conference participation

   24h Move

   +1.0%

   CEO scheduled for fireside chat at BofA Securities health care conference.

5. Mar 31

   Regulatory designation

   24h Move

   +10.5%

   FDA granted RMAT designation to CB-011 based on phase 1 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

crispr genome-editing

1 terms

crispr genome-editing medical

"a leading clinical-stage CRISPR genome-editing biopharmaceutical company"

A gene-editing technique that uses a molecular 'scissor' to find and change specific DNA sequences inside living cells. Think of it like a search-and-replace tool for genetic code that can remove, repair, or insert bits of DNA to alter traits or fix faulty genes. Investors watch it because successful applications can create new therapies, crops, or diagnostics with potentially large markets, but development is costly and faces scientific and regulatory risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35pm ET in New York.

For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Caribou’s chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow the company @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contact:
Peggy Vorwald, PhD
investor.relations@cariboubio.com
media@cariboubio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Caribou Biosciences (CRBU) present at the 2026 Jefferies Global Healthcare Conference?

Caribou Biosciences will participate in a fireside chat on June 4, 2026, at 2:35 p.m. ET. According to Caribou, the event takes place in New York as part of the Jefferies Global Healthcare Conference.

Who will represent Caribou Biosciences (CRBU) at the 2026 Jefferies healthcare conference?

Caribou Biosciences will be represented by Rachel Haurwitz, PhD, its president and chief executive officer. According to Caribou, she will participate in a scheduled fireside chat during the conference program.

How can investors access the Caribou Biosciences (CRBU) webcast from the 2026 Jefferies Global Healthcare Conference?

Investors can access the webcast through the Events page on Caribou’s website. According to Caribou, the page will provide the live webcast link and related event information for viewers.

Will a replay of Caribou Biosciences’ 2026 Jefferies conference fireside chat be available?

Yes, a replay will be available on Caribou’s website for at least 30 days. According to Caribou, archived webcasts can be accessed via the Events section after the live presentation.

What type of event is Caribou Biosciences (CRBU) holding at the 2026 Jefferies Global Healthcare Conference?

Caribou Biosciences is holding a fireside chat session featuring its CEO, Rachel Haurwitz. According to Caribou, this discussion is part of the official conference agenda on June 4, 2026.